FENC — Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Product Sales: $15.1 million, a 73% increase year-over-year from $8.8 million in Q1 2025.
• Operating Expenses: Approximately $14 million, reflecting a $6 million increase primarily in SG&A due to expanded marketing and commercial headcount.
• Cash Position: Cash and cash equivalents stood at $40.1 million as of March 31, 2026, with a net increase of $3.3 million during the quarter.
• Operating Cash Flow: Positive cash flow of $2.3 million was reported.
• Future Cash Flow: Anticipated quarterly fluctuations in cash position, with expectations for positive cash flow in Q3 and sustained growth in the second half of 2026.

2. Strategic Updates and Business Highlights

• Commercial Initiatives: Launched "Project Ignite" to enhance commercial execution, expanding the sales team and increasing prescriber targets from 1,300 to over 5,000.
• Fennec HEARS Program: Significant growth in patient support services, with a 48% quarter-over-quarter increase in completed infusions and an 80% conversion rate from prescriptions to therapy.
• Clinical Development: Initiated a third investigator-initiated study (IST) for PEDMARK in adolescent and young adult (AYA) and adult patients, with positive clinical interest noted.
• Market Access: Engaged with Group Purchasing Organizations (GPOs) to facilitate broader adoption of PEDMARK.

3. Forward Guidance and Outlook

• Growth Expectations: Management expressed confidence in continued growth throughout 2026, supported by strong early indicators in Q2.
• Revenue Projections: Anticipated sustained revenue growth driven by increased adoption of PEDMARK and ongoing commercial initiatives.
• Cash Utilization: Expected to utilize approximately $50 million in cash operating expenses in 2026, with over 60% in the first half.

4. Bad News, Challenges, or Points of Concern

• Milestone Payments: The company does not expect to receive a milestone payment from Norgine related to the German market.
• Operational Risks: Potential fluctuations in cash position due to collection cycles and the ramp-up period for new sales representatives.
• Market Sensitivity: The AYA market is described as promotionally sensitive, requiring effective communication of unmet needs.

5. Notable Q&A Insights

• Growth Drivers: The increase in sales was attributed to a balanced approach between new account additions and deeper utilization in existing accounts, with early signs of success from new hires.
• Investigator-Initiated Trials: The rationale for pursuing ISTs is to establish PEDMARK's position in new patient populations and generate data for potential regulatory discussions.
• High-Volume Prescribers: The company targets both academic and community oncologists, with a balanced approach to engagement.
• Future Trials: Interest in additional ISTs is high, with ongoing discussions about potential regulatory implications as data matures.

Overall, Fennec Pharmaceuticals reported a strong quarter with significant sales growth and strategic advancements, while also acknowledging certain challenges and operational risks ahead.